- Home
- LXEH vs NVNO Comparison
LXEH vs NVNO Comparison
Compare LXEH & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXEH | NVNO |
|---|---|---|
| Founded | 2001 | 1987 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 7.3M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LXEH | NVNO |
|---|---|---|
| Price | $0.27 | $9.64 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 28.0K |
| Earning Date | 03-15-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,585,942.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.18 | $9.42 |
| 52 Week High | $50.08 | $196.70 |
Technical Indicators
Market Signals| Indicator | LXEH | NVNO |
|---|---|---|
| Relative Strength Index (RSI) | 52.61 | 66.15 |
| Support Level | $0.20 | $9.42 |
| Resistance Level | $0.39 | $12.42 |
| Average True Range (ATR) | 0.06 | 1.28 |
| MACD | 0.01 | 0.14 |
| Stochastic Oscillator | 31.74 | 74.77 |
Price Performance
Historical ComparisonAbout LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.